The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies, and growing focus on precision medicine.
# Discrepancies in HPAPI Banding Systems
-:Strategies Adopted by Major Leaders:-
Restraints:
# Requirement of Large Investments# Discrepancies in HPAPI Banding Systems
# Uncertainties Associated With Products
# High Risk of Cross-Contamination
Opportunities:
# Growing Opportunities for CMOS and CDMOS
# Emerging Markets
Challenges:
# Need for Appropriate Process Designs
# Constant Evolution of Industry Standards and Technologies
Download the PDF Brochure for More Details@ http://bit.ly/2xmvDvb
The objectives of this study are as follows:
The objectives of this study are as follows:
- To define, describe, and forecast the global HPAPI market on the basis of type, type of manufacturer, type of synthesis, therapeutic application, and region
- To provide detailed information about factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets with respect to the individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments of North America, Europe, Asia, and the Rest of the World (RoW)
- To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze competitive developments such as agreements, partnerships, collaborations, and alliances; mergers and acquisitions; expansions; and R&D activities in the global HPAPI market
-:Strategies Adopted by Major Leaders:-
Agreements, partnerships, collaborations, and alliances accounted for the largest share of the overall growth strategies followed by key players between 2015 and 2018.
Some of the key players in the HPAPIs market include Pfizer (US), Novartis (Switzerland), Merck (US), Teva (Israel), Mylan (US), Boehringer Ingelheim (Germany), Sanofi (France), F. Hoffmann-La Roche (Switzerland), AbbVie (US), Eli Lilly (US), Mylan (US), and Bristol-Myers Squibb (US).
Pfizer held the leading position in the HPAPIs market in 2017. The dominant position of the company can be attributed to its exhaustive product portfolio. The company has been operating in the APIs market for more than a decade and has a strong brand image, which gives it a competitive edge over other players. To remain competitive and strengthen its market position, the company primarily focuses on adopting both organic and inorganic growth strategies such as acquisitions and expansions. In 2015, Pfizer acquired Anacor Pharmaceuticals (US), a leading biopharmaceutical company and Hospira (US) a global leader in biosimilars. Such acquisitions enabled the company to expand its product offerings and global market presence.
Novartis International AG held the second position in the HPAPIs market. The company has a strong brand recognition among end users and a wide global presence. In order to maintain its leading market position, the company invests a significant amount of its revenue in R&D activities. In 2016, the company invested 18.6% of its total revenue (USD 9.0 billion) on R&D.
This significant investment enables the company to launch innovative and technologically advanced products in the market. The company also focuses on inorganic growth strategies to strengthen its position in the market. For instance, in June 2016, Novartis entered into a licensing and collaboration agreement with Xencor (US), a biopharmaceutical company that develops engineered monoclonal antibodies. The purpose of this agreement was to develop bispecific antibodies for treating cancer. Such approaches help the company to strengthen its position in the global HPAPIs market.
Agreements, partnerships, collaborations, and alliances accounted for the largest share of the overall growth strategies followed by key players between 2015 and 2018.
Some of the key players in the HPAPIs market include Pfizer (US), Novartis (Switzerland), Merck (US), Teva (Israel), Mylan (US), Boehringer Ingelheim (Germany), Sanofi (France), F. Hoffmann-La Roche (Switzerland), AbbVie (US), Eli Lilly (US), Mylan (US), and Bristol-Myers Squibb (US).
Pfizer held the leading position in the HPAPIs market in 2017. The dominant position of the company can be attributed to its exhaustive product portfolio. The company has been operating in the APIs market for more than a decade and has a strong brand image, which gives it a competitive edge over other players. To remain competitive and strengthen its market position, the company primarily focuses on adopting both organic and inorganic growth strategies such as acquisitions and expansions. In 2015, Pfizer acquired Anacor Pharmaceuticals (US), a leading biopharmaceutical company and Hospira (US) a global leader in biosimilars. Such acquisitions enabled the company to expand its product offerings and global market presence.
Novartis International AG held the second position in the HPAPIs market. The company has a strong brand recognition among end users and a wide global presence. In order to maintain its leading market position, the company invests a significant amount of its revenue in R&D activities. In 2016, the company invested 18.6% of its total revenue (USD 9.0 billion) on R&D.
This significant investment enables the company to launch innovative and technologically advanced products in the market. The company also focuses on inorganic growth strategies to strengthen its position in the market. For instance, in June 2016, Novartis entered into a licensing and collaboration agreement with Xencor (US), a biopharmaceutical company that develops engineered monoclonal antibodies. The purpose of this agreement was to develop bispecific antibodies for treating cancer. Such approaches help the company to strengthen its position in the global HPAPIs market.
No comments:
Post a Comment